{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T12:08:27Z","timestamp":1782389307970,"version":"3.54.5"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T00:00:00Z","timestamp":1651104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>The role of patent foramen ovale (PFO) in stroke was debated for decades. Randomized clinical trials (RCTs) have shown fewer recurrent events after PFO closure in patients with cryptogenic stroke (CS). However, in clinical practice, treating stroke patients with coexisting PFO raises some questions. This brief review summarizes current knowledge and challenges in handling stroke patients with PFO and identifies issues for future research. The rationale for PFO closure was initially based on the concept of paradoxical embolism from deep vein thrombosis (DVT). However, RCTs did not consider such details, limiting their impact from a pathophysiological perspective. Only a few studies explored the coexistence of PFO and DVT in CS with varying results. Consequently, the PFO itself might play a role as a prothrombotic structure. Transesophageal echocardiography thus appears most appropriate for PFO detection, while a large shunt size or an associated atrial septum aneurysm qualify for a high-risk PFO. For drug-based treatment alone, studies did not find a definite superiority of oral anticoagulation over antiplatelet therapy. Remarkably, drug-based treatment in addition to PFO closure was not standardized in RCTs. The available literature rarely considers patients with transient ischemic attack (TIA), over 60 years of age, and competing etiologies like atrial fibrillation. In summary, RCTs suggest efficacy for closure of high-risk PFO only in a small subgroup of stroke patients. However, research is also needed to reevaluate the pathophysiological concept of PFO-related stroke and establish strategies for older and TIA patients and those with competing risk factors or low-risk PFO.<\/jats:p>","DOI":"10.3389\/fneur.2022.855656","type":"journal-article","created":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T14:29:49Z","timestamp":1651242589000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Current Challenges and Future Directions in Handling Stroke Patients With Patent Foramen Ovale\u2014A Brief Review"],"prefix":"10.3389","volume":"13","author":[{"given":"Charlotte","family":"Huber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf","family":"Wachter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann","family":"Pelz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Michalski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,4,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"711","DOI":"10.3238\/arztebl.2019.0711","article-title":"The frequency and timing of recurrent stroke - an analysis of routine health insurance data","volume":"116","author":"Stahmeyer","year":"2019","journal-title":"Dtsch Arztebl Int"},{"key":"B2","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1161\/01.STR.24.1.35","article-title":"Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment","volume":"24","author":"Adams","year":"1993","journal-title":"Stroke."},{"key":"B3","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/S1474-4422(13)70310-7","article-title":"Embolic strokes of undetermined source: the case for a new clinical construct","volume":"13","author":"Hart","year":"2014","journal-title":"Lancet Neurol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1161\/STROKEAHA.109.547828","article-title":"Patent foramen ovale in cryptogenic stroke: incidental or pathogenic?","volume":"40","author":"Alsheikh-Ali","year":"2009","journal-title":"Stroke."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1161\/CIRCULATIONAHA.104.524371","article-title":"Patent foramen ovale and stroke","volume":"112","author":"Homma","year":"2005","journal-title":"Circulation."},{"key":"B6","doi-asserted-by":"publisher","first-page":"281","DOI":"10.3389\/fneur.2020.00281","article-title":"Epidemiology of patent foramen ovale in general population and in stroke patients: a narrative review","volume":"11","author":"Koutroulou","year":"2020","journal-title":"Front Neurol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/1745-6215-12-185","article-title":"The Risk of Paradoxical Embolism (RoPE) study: developing risk models for application to ongoing randomized trials of percutaneous patent foramen ovale closure for cryptogenic stroke","volume":"12","author":"Kent","year":"2011","journal-title":"Trials."},{"key":"B8","first-page":"11","article-title":"Patent foramen ovale and paradoxical embolization: a historical perspective","volume":"66","author":"Lippmann","year":"1993","journal-title":"Yale J Biol Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1212\/WNL.36.10.1356","article-title":"Paradoxical cerebral embolism: eight cases","volume":"36","author":"Biller","year":"1986","journal-title":"Neurology."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1111\/ijs.12630","article-title":"Design of randomized, double-blind, evaluation in secondary stroke prevention comparing the EfficaCy and safety of the oral Thrombin inhibitor dabigatran etexilate vs. acetylsalicylic acid in patients with Embolic Stroke of Undetermined Source (RE-SPECT ESUS)","volume":"10","author":"Diener","year":"2015","journal-title":"Int J Stroke."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1056\/NEJMoa1802686","article-title":"Rivaroxaban for stroke prevention after embolic stroke of undetermined source","volume":"378","author":"Hart","year":"2018","journal-title":"N Engl J Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1161\/01.CIR.0000017498.88393.44","article-title":"Effect of medical treatment in stroke patients with patent foramen ovale: patent foramen ovale in Cryptogenic Stroke Study","volume":"105","author":"Homma","year":"2002","journal-title":"Circulation."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1056\/NEJMoa1705915","article-title":"Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke","volume":"377","author":"Mas","year":"2017","journal-title":"N Engl J Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1161\/STROKEAHA.120.031237","article-title":"Dabigatran or aspirin after embolic stroke of undetermined source in patients with patent foramen ovale: results from RE-SPECT ESUS","volume":"52","author":"Diener","year":"2021","journal-title":"Stroke."},{"key":"B15","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1007\/s10557-020-07068-9","article-title":"Comparison of antithrombotic strategies in patients with cryptogenic stroke and patent foramen ovale: an updated meta-analysis","volume":"35","author":"Angelini","year":"2021","journal-title":"Cardiovasc Drugs Ther."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1056\/NEJMoa1301440","article-title":"Closure of patent foramen ovale versus medical therapy after cryptogenic stroke","volume":"368","author":"Carroll","year":"2013","journal-title":"N Engl J Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1056\/NEJMoa1009639","article-title":"Closure or medical therapy for cryptogenic stroke with patent foramen ovale","volume":"366","author":"Furlan","year":"2012","journal-title":"N Engl J Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1056\/NEJMoa1211716","article-title":"Percutaneous closure of patent foramen ovale in cryptogenic embolism","volume":"368","author":"Meier","year":"2013","journal-title":"N Engl J Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1016\/j.jacc.2018.02.046","article-title":"Cryptogenic stroke and high-risk patent foramen ovale: the DEFENSE-PFO trial","volume":"71","author":"Lee","year":"2018","journal-title":"J Am Coll Cardiol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1056\/NEJMoa1707404","article-title":"Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke","volume":"377","author":"S\u00f8ndergaard","year":"2017","journal-title":"N Engl J Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1056\/NEJMoa1610057","article-title":"Long-term outcomes of patent foramen ovale closure or medical therapy after stroke","volume":"377","author":"Saver","year":"2017","journal-title":"N Engl J Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e007146","DOI":"10.1161\/JAHA.117.007146","article-title":"Patent foramen ovale closure for stroke prevention and other disorders","volume":"7","author":"Collado","year":"2018","journal-title":"J Am Heart Assoc."},{"key":"B23","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.1212\/WNL.0000000000005739","article-title":"Percutaneous patent foramen ovale closure for secondary stroke prevention: network meta-analysis","volume":"91","author":"Tsivgoulis","year":"2018","journal-title":"Neurology."},{"key":"B24","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1177\/2396987319863606","article-title":"Consensus statements and recommendations from the ESO-Karolinska Stroke Update Conference, Stockholm 11-13 November 2018","volume":"4","author":"Ahmed","year":"2019","journal-title":"Eur Stroke J."},{"key":"B25","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1212\/WNL.0000000000009443","article-title":"Practice advisory update summary: patent foramen ovale and secondary stroke prevention: report of the Guideline Subcommittee of the American Academy of Neurology","volume":"94","author":"Mess\u00e9","year":"2020","journal-title":"Neurology."},{"key":"B26","unstructured":"Kryptogener Schlaganfall und offenes Foramen ovale, S2e-Leitlinie, 2018 in: Deutsche Gesellschaft f\u00fcr Neurologie (Hrsg.), Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie\n            DienerHC\n            GrauA\n            BaldusS\n            GhanemA\n            Gr\u00f6schelK\n            LiebetrauC"},{"key":"B27","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1177\/2396987320939804","article-title":"An assessment of annual procedure volumes and therapy adoption of transcatheter closure of patent foramen ovale in four European countries","volume":"6","author":"Pietzsch","year":"2021","journal-title":"Eur Stroke J."},{"key":"B28","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1080\/13696998.2019.1611587","article-title":"Cost-effectiveness of percutaneous closure of a patent foramen ovale compared with medical management in patients with a cryptogenic stroke: from the US payer perspective","volume":"22","author":"Volpi","year":"2019","journal-title":"J Med Econ."},{"key":"B29","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13643-021-01626-4","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"10","author":"Page","year":"2021","journal-title":"Syst Rev."},{"key":"B30","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1161\/01.STR.0000106137.42649.AB","article-title":"Increased pelvic vein thrombi in cryptogenic stroke: results of the Paradoxical Emboli from Large Veins in Ischemic Stroke (PELVIS) study","volume":"35","author":"Cramer","year":"2004","journal-title":"Stroke."},{"key":"B31","doi-asserted-by":"publisher","first-page":"336","DOI":"10.3389\/fneur.2020.00336","article-title":"Deep vein thrombosis and pulmonary embolism among patients with a cryptogenic stroke linked to patent foramen ovale-A review of the literature","volume":"11","author":"Zietz","year":"2020","journal-title":"Front Neurol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1161\/STROKEAHA.114.005539","article-title":"Diagnostic yield of pelvic magnetic resonance venography in patients with cryptogenic stroke and patent foramen ovale","volume":"45","author":"Liberman","year":"2014","journal-title":"Stroke."},{"key":"B33","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s11239-009-0317-3","article-title":"Interatrial thrombus-in-transit resulting in paradoxical thromboembolism","volume":"29","author":"Khoobiar","year":"2010","journal-title":"J Thromb Thrombolysis."},{"key":"B34","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1111\/echo.15018","article-title":"The evolving role of echocardiography in the assessment of patent foramen ovale in patients with left-side thromboembolism","volume":"38","author":"Filomena","year":"2021","journal-title":"Echocardiography."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000506433","article-title":"Morphometric features of patent foramen ovale as a risk factor of cerebrovascular accidents: a systematic review and meta-analysis","volume":"49","author":"Ho\u0142da","year":"2020","journal-title":"Cerebrovasc Dis."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1007\/s10554-018-1406-1","article-title":"Echocardiographic features of PFOs and paradoxical embolism: a complicated puzzle","volume":"34","author":"Aggeli","year":"2018","journal-title":"Int J Cardiovasc Imaging."},{"key":"B37","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1016\/j.jacc.2020.02.068","article-title":"Atrial septal aneurysm, shunt size, and recurrent stroke risk in patients with patent foramen ovale","volume":"75","author":"Turc","year":"2020","journal-title":"J Am Coll Cardiol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"e0242885","DOI":"10.1371\/journal.pone.0242885","article-title":"Role of transoesophageal echocardiography in detecting patent foramen ovale in stroke patients aged \u2264 60 years: a retrospective study","volume":"15","author":"Najjar","year":"2020","journal-title":"PLoS ONE."},{"key":"B39","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/0735-1097(91)90705-E","article-title":"Superiority of transesophageal echocardiography in detecting cardiac source of embolism in patients with cerebral ischemia of uncertain etiology","volume":"17","author":"Pearson","year":"1991","journal-title":"J Am Coll Cardiol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"e0216530","DOI":"10.1371\/journal.pone.0216530","article-title":"The cardiac diagnostic work-up in stroke patients-A subanalysis of the Find-AFRANDOMISED trial","volume":"14","author":"Wasser","year":"2019","journal-title":"PLoS ONE."},{"key":"B41","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1002\/ana.24609","article-title":"Transcranial Doppler versus transthoracic echocardiography for the detection of patent foramen ovale in patients with cryptogenic cerebral ischemia: a systematic review and diagnostic test accuracy meta-analysis","volume":"79","author":"Katsanos","year":"2016","journal-title":"Ann Neurol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.3390\/genes12121953","article-title":"The genetic landscape of patent foramen ovale: a systematic review","volume":"12","author":"Paolucci","year":"2021","journal-title":"Genes."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/S1474-4422(18)30319-3","article-title":"Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial","volume":"17","author":"Kasner","year":"2018","journal-title":"Lancet Neurol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s42466-021-00114-3","article-title":"Closure or medical therapy of patent foramen ovale in cryptogenic stroke: prospective case series","volume":"3","author":"Poli","year":"2021","journal-title":"Neurol Res Pract."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1161\/CIRCULATIONAHA.121.055176","article-title":"Predictors of atrial fibrillation development in patients with embolic stroke of undetermined source: an analysis of the RE-SPECT ESUS trial","volume":"144","author":"Bahit","year":"2021","journal-title":"Circulation."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1161\/STROKEAHA.120.032002","article-title":"Cancer and embolic stroke of undetermined source","volume":"52","author":"Navi","year":"2021","journal-title":"Stroke."},{"key":"B47","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1001\/jama.2021.20956","article-title":"Heterogeneity of treatment effects in an analysis of pooled individual patient data from randomized trials of device closure of patent foramen ovale after stroke","volume":"326","author":"Kent","year":"2021","journal-title":"JAMA."},{"key":"B48","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s11936-019-0786-4","article-title":"Cryptogenic stroke: diagnostic workup and management","volume":"21","author":"Mac Grory","year":"2019","journal-title":"Curr Treat Options Cardiovasc Med."},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-021-08867-0","article-title":"Nickel hypersensitivity to atrial septal occluders: smoke without fire?","author":"Apostolos","year":"2021","journal-title":"Clin Rev Allergy Immunol."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.855656\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T14:29:53Z","timestamp":1651242593000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.855656\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,28]]},"references-count":49,"alternative-id":["10.3389\/fneur.2022.855656"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2022.855656","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,28]]},"article-number":"855656"}}